Beyond Air (XAIR) Q2 2025 earnings summary

Executive summary

• Achieved a 60% quarter-over-quarter increase in total hospital clients, reflecting strong commercial momentum and successful marketing initiatives.

• Revenue for Q2 FY2025 was $0.8M, up from $0.2M in Q2 FY2024, driven by increased hospital contracts for LungFit PH; cost of revenue exceeded revenue due to device upgrades and inventory provisions.

• Strategic partnerships established with HealthCare Links, TrillaMed, and Business Asia Consultants to expand U.S. and international reach.

• The company implemented cost-saving measures, including a 30% staff reduction, back office downsizing, and pausing the VCAP study to conserve capital.

• Management believes recent actions and new commercial agreements will help address liquidity concerns and support ongoing operations.

Financial highlights

• Q2 FY2025 revenue was $0.8 million, up from $0.2 million in Q2 FY2024; six-month revenue was $1.5 million vs. $0.3 million prior year.

• Gross margin loss of $1.1 million in Q2 FY2025, compared to a $0.2 million loss in the prior year, due to $0.7 million in one-time device upgrade costs and $0.8 million in non-cash inventory/depreciation charges.

• R&D expenses decreased to $4.6 million from $7.1 million year-over-year; SG&A expenses fell to $7.2 million from $10.2 million.

• Net loss for Q2 FY2025 was $13.4 million ($0.28/share), improved from $16.2 million ($0.51/share) in Q2 FY2024.

• Cash, cash equivalents, and marketable securities at quarter-end were $28.4 million; pro forma $18.5 million after recent financial transactions.

Outlook and guidance

• Expect continued contract growth, though percentage increases may moderate as the base grows.

• Gross margins projected to turn positive in the March 2025 quarter, with a target of 60%-65% by the end of calendar 2025.

• Anticipate reduction in cash burn by at least one-third in Q3 FY2025 due to cost-cutting measures.

• International expansion expected to begin contributing in the first half of 2025, with some margin impact.

• Future capital needs depend on commercialization success, regulatory approvals, and potential additional fundraising.